Naples

• A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended
  2024-512202-25-00 4 2023-02-27 Irritability associated with autistic disorder in children and adolesc
• Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth … Ended
  2024-512258-91-00 5 2023-02-03 Generalized Myasthenia Gravis (gMG)
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• A phase II study of linperlisib (YY-20394) in patients with relapsed or refractory peripheral T/NK cell or Cutaneous T Cell lymphoma Ended
  2022-501431-16-00 4 2023-01-17 Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lympho
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended
  2023-504238-23-00 5 2023-01-17 Hepatitis B, Chronic
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 4 2023-01-17 Asthma
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhi … Ended
  2022-500652-37-00 4 2022-12-01 Advanced melanoma refractory to prior checkpoint inhibitor therapy
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Dru … Ended
  2024-513708-33-00 1 2022-11-23 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• VItamin C in Thermal injuRY: The VICToRY Trial A phase III multi-center randomized trial Ended
  2023-504772-21-00 4 2022-11-22 Severely burned patients
• Safety and efficacy of PC945 (opelconazole) in combination with other antifungal therapy for the treatment of refractory invasive pulmonary … Ended
  2024-511281-36-00 5 2022-11-17 Refractory Invasive Pulmonary Aspergillosis
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Ended
  2023-508404-37-00 3 2022-10-26 Non-muscle Invasive Bladder Cancer
• A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti–LAG-3) and INCAGN02390 (Anti–TI … Ended
  2023-504270-38-00 4 2022-10-18 In participants with PD-L1–positive and systemic therapy–naive R/M SCC
• A study to find out whether BI 1015550 improves lung function in people with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) Ended
  2024-512803-37-00 5 2022-10-05 Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended
  2023-505458-16-00 5 2022-09-13 Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpressio
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache Ended
  2024-510729-24-00 6 2022-09-01 Chronic Migrane, Migrane, Medication Overuse Headache
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended
  2022-500363-12-00 4 2022-08-24 SARS CoV-2 (COVID-19)

Showing 1,033–1,056 of 1,177 trials